Influence on hormone levels, lipid metabolism and reversibility of endocrinological changes after leuprorelin acetate depot therapy.
The effect of leuprorelin acetate depot on the endocrine system and on lipid metabolism was evaluated in a multicentre, noncomparative study. During the first month of treatment, suppression of serum oestradiol levels to below 20 pg/ml was achieved and luteinising hormone and follicle-stimulating hormone levels were reduced to less than 50% of pretreatment values. A negative influence on lipid metabolism was not recorded. The high-density lipoprotein/low-density lipoprotein ratio did not change during therapy. Resumption of menstruation occurred within a mean period of 3 months after the last leuprorelin acetate depot injection.
Bühler
K
K
Abteilung für Gynäkologie, Universitätsklinikum Essen, Germany.
Winkler
U
U
Schindler
A E
AE
D015519:Bone Density / Q000187:drug effects; D003692:Delayed-Action Preparations; D004958:Estradiol / Q000097:blood*; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006065:Gonadotropins, Pituitary / Q000097:blood*; D006801:Humans; D016729:Leuprolide / Q000494:pharmacology / Q000627:therapeutic use*; D050356:Lipid Metabolism; D008074:Lipoproteins / Q000097:blood / Q000187:drug effects; D008075:Lipoproteins, HDL / Q000097:blood / Q000187:drug effects; D008077:Lipoproteins, LDL / Q000097:blood / Q000187:drug effects; D007986:Luteinizing Hormone / Q000097:blood; D011374:Progesterone / Q000097:blood*; D014594:Uterine Neoplasms / Q000188:drug therapy / Q000378:metabolism
D003692:Delayed-Action Preparations; D006065:Gonadotropins, Pituitary; D008074:Lipoproteins; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D011374:Progesterone; D004958:Estradiol; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D016729:Leuprolide